Digma aims to harness the power of the small intestine to empower patients and physicians with safe, simple and effective new therapies for type 2 diabetes that dramatically improve their quality of life and long-term health outcomes.
We are developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), that aims to restore the body’s natural ability to control blood glucose levels. The treatment targets the duodenal submucosa which is central to nutrient sensing and metabolic signaling .
Our product is compatible with standard gastrointestinal endoscopes and the EGM procedure is being developed so that it can be performed in a standard GI endoscopy suite without requiring additional imaging equipment. Our goal is to provide patients with durable improvement in glycemic control with minimal side effects and without requiring additional daily medical therapy.
The EGM procedure is currently being evaluated in clinical studies. To learn more about our clinical program, please contact us.
Location: Israel, Tel Aviv, Hertsliyah
Member count: 11-50
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Arkin Hold... | arkinholdi... |
Mentions in press and media 10
| Date | Title | Description | Source |
| 27.12.2022 | Minerva Surgical Announces $30 Million Private Placement of ... | /EIN News/ -- SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq:... | einpresswi... |
| 27.12.2022 | Minerva Surgical Announces $30 Million Private Placement of ... | - | globenewsw... |
| 22.03.2021 | Accelmed closes $400M fund, invests in medication adherence ... | “Over the past decade, we have served as a trusted value-add partner to health-tech companies and ma... | medcitynew... |
| 18.03.2021 | Accelmed closes $400M healthtech fund | Accelmed Partners has closed its second flagship fund on a hard cap of $400 million, passing its ori... | pitchbook.... |
| 17.03.2021 | Accelmed closes $400M fund amid high healthtech demand | The private equity firm Accelmed Partners has closed its second fund, with plans to invest $400 mill... | fiercebiot... |
| 17.03.2021 | Healthtech demand has ‘never been greater’ says Accelmed, as... | Accelmed Partners has hit a $400m hard cap final close for its second fundraise, saying demand for t... | altassets.... |
| 17.03.2021 | Accelmed closes $400M fund amid high healthtech demand | The private equity firm Accelmed Partners has closed its second fund, with plans to invest $400 mill... | fiercebiot... |
| 17.03.2021 | Accelmed Partners Raises $400 Million to Invest in Commercia... | AVENTURA, Fla.--(BUSINESS WIRE)--Mar 17, 2021-- Accelmed Partners (“Accelmed”), a private equity fi... | oaoa.com/n... |
| 02.04.2018 | STRATA Skin Sciences Announces $17M Equity Financing Led by ... | HORSHAM, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- STRATA Skin Sciences (NASDAQ:SSKN) (“STRATA”) a med... | citybizlis... |
| - | Accelmed closes $400M fund, invests in medication adherence ... | Private equity firm Accelmed Partners recently closed a $400 million oversubscribed second fund. The... | medcitynew... |